The Patient Outcomes With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Receiving Aumolertinib As First-Line Treatment
June 2024
in “
Journal of Clinical Oncology
”
Studysummary In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A study involving 33 patients with advanced non-small cell lung cancer (NSCLC) treated with aumolertinib as a first-line therapy showed promising results. The objective response rate (ORR) was 65.2%, and the disease control rate (DCR) was 91.3%. Patients experienced improvements in general health status, functional status, and key symptoms such as cough, sore mouth or tongue, and various types of pain. These findings align with the results of the AENEAS trial, indicating that aumolertinib is effective and well-tolerated in treating EGFR-mutated advanced NSCLC.
